Clinical Trial Update: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating adding relatlimab to standard immunotherapy for recurrent or metastatic nasopharyngeal carcinoma, and the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING